Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
about
Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infectionTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensThe role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.A novel murine model of established Staphylococcal bone infection in the presence of a fracture fixation plate to study therapies utilizing antibiotic-laden spacers after revision surgery.Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection ModelTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions.Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection3D printed bioceramics for dual antibiotic delivery to treat implant-associated bone infectionIn Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Genomic characterization and assessment of the virulence and antibiotic resistance of the novel species Paenibacillus sp. strain VT-400, a potentially pathogenic bacterium in the oral cavity of patients with hematological malignanciesAntibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection.Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.Telavancin: a review of its use in patients with nosocomial pneumonia.Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection.In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection.Disruption of staphylococcal aggregation protects against lethal lung injury.
P2860
Q33622963-4CB0C6B4-4FF8-4FD5-9ED0-752B4CEE6628Q33788308-37E19A00-D605-446C-905A-15AAEBA2EFEBQ34672655-D378E3C8-8AB5-4ECC-9114-17BFC3A52ABEQ34810456-A64DBEEC-ACA9-4F42-A992-C458AB3971A3Q35859914-5C29C3CD-FA46-47E6-B6C4-BE6D30BF17CDQ35905561-81C0D487-1456-412C-85CD-2A903982CE60Q35941253-29CBAE46-C16C-4EB2-8019-092CCFAE246CQ36018731-8A378D45-7A7D-49BD-8D69-341109E22441Q36292752-375A916E-7837-4C36-9F9A-558DA4832B96Q36328108-F5632082-6C1E-4246-B33C-B45EFEAE30A8Q36439072-B3AE5472-F302-4E02-A3E5-C903CC9EB893Q36558524-79036F40-18E7-4263-8023-149307084F4DQ36599959-D1ADA0A3-7B3A-442B-BEED-00035EBA8E4FQ37119959-1AA66C71-C36D-4671-BE21-9409E7D7629CQ37263918-5E435556-F012-4F13-8455-D54460B1A134Q37696606-AC30DCDE-2710-40EE-8AB1-4EADDA4DD848Q38048845-2BEB1104-D3E3-4964-ABD0-0CA5ED584C26Q38159966-2ECD7E39-60A4-4DA5-8659-2FC87FF890F8Q38266421-35ECA9D4-DA1A-4593-ACDE-D84B6802BE3BQ38575714-A525A7C1-156B-40CA-8C04-125C5C8B5ED8Q38646905-7989400C-78CA-4F31-8514-C62C37683854Q38829519-4161EB04-0A6C-41B9-9130-6BC461D04AABQ38892614-CB58842A-CB8C-4A78-B447-F27F4747753DQ40018152-53321D9B-BB9E-4762-8D1D-EFFB72C370B4Q42107088-4B000F95-00BC-419B-A2C9-D8257A9FF522Q50047637-E486E24D-3DEE-4161-AA05-78C9F2836094
P2860
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Comparative efficacies of huma ...... s in a murine pneumonia model.
@ast
Comparative efficacies of huma ...... s in a murine pneumonia model.
@en
Comparative efficacies of huma ...... s in a murine pneumonia model.
@nl
type
label
Comparative efficacies of huma ...... s in a murine pneumonia model.
@ast
Comparative efficacies of huma ...... s in a murine pneumonia model.
@en
Comparative efficacies of huma ...... s in a murine pneumonia model.
@nl
prefLabel
Comparative efficacies of huma ...... s in a murine pneumonia model.
@ast
Comparative efficacies of huma ...... s in a murine pneumonia model.
@en
Comparative efficacies of huma ...... s in a murine pneumonia model.
@nl
P2093
P2860
P356
P1476
Comparative efficacies of huma ...... s in a murine pneumonia model.
@en
P2093
David P Nicolau
Jared L Crandon
Joseph L Kuti
P2860
P304
P356
10.1128/AAC.00062-10
P407
P577
2010-09-13T00:00:00Z